newsfilter
← Latest News
GlobeNewswire·

SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML – – Positive Phase 2 Data for SLS009 in R/R AML Accepted for Presentation at ASH 2025; Initiation of Trial Including Newly Diagnosed First-Line